Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity

Detalhes bibliográficos
Autor(a) principal: Araujo, Magali de [UNIFESP]
Data de Publicação: 2002
Outros Autores: Seguro, Antonio Carlos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://repositorio.unifesp.br/11600/42610
https://www.intmedpress.com/journals/avt/abstract.cfm?id=1223&pid=88
Resumo: Objectives: Indinavir is a widely prescribed protease inhibitor in the treatment of HIV infection. It has been associated with nephrolithiasis, crystalluria and tubulointerstitial nephritis. Nelfinavir is another protease inhibitor used successfully in AIDS treatment. The objective of this study was to evaluate the effect of both indinavir and nelfinavir individually, and in association with trimethoprim-sulfamethoxazole (TMP/SMX), on renal function in Wistar rats.Methods: Doses of indinavir (80 mg/kg body weight [BW] daily), nelfinavir (75 mg/kg BW daily) and TMP/SMX (100 mg TMP/kg BW daily) were given by gavage for 15 days. Seven groups were studied: control, vehicle, TMP/SMX, indinavir, indinavir+TMP/SMX, nelfinavir, and nelfinavir+TMP/SMX.Results: No changes were observed in body weight, urine volume and blood pressure. The vehicle group did not differ from the control group. TMP/SMX induced a small decrease in inulin clearance with no tubular alterations. Indinavir decreased inulin clearance (indinavir: 0.48 +/- 0.03 vs control: 0.93 +/- 0.08, P<0.001) and renal blood flow (indinavir: 6.2 +/- 0.2 vs control: 8.0 +/- 0.3, P<0.05). These effects were potentiated by TMP/SMX, which produced high vasoconstriction associated with alterations in tubular functions, characterised by increased fractional excretion of sodium (indinavir+TMP/SMX: 1.14 +/- 0.16 vs control: 0.39 +/- 0.07, P<0.01). Nelfinavir either alone or in combination with TMP/SMX did not change the renal function of the rats.Conclusion: These results suggest that indinavir nephrotoxicity in rats is potentiated by TMP/SMX and that nelfinavir alone or in combination with TMP/SMX is not nephrotoxic.
id UFSP_1077843878a9e203c0efbe5e1a63b369
oai_identifier_str oai:repositorio.unifesp.br:11600/42610
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Araujo, Magali de [UNIFESP]Seguro, Antonio CarlosUniversidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)2018-06-15T13:50:16Z2018-06-15T13:50:16Z2002-09-01Antiviral Therapy. London: Int Medical Press Ltd, v. 7, n. 3, p. 181-184, 2002.1359-6535http://repositorio.unifesp.br/11600/42610https://www.intmedpress.com/journals/avt/abstract.cfm?id=1223&pid=88WOS:000179501500005Objectives: Indinavir is a widely prescribed protease inhibitor in the treatment of HIV infection. It has been associated with nephrolithiasis, crystalluria and tubulointerstitial nephritis. Nelfinavir is another protease inhibitor used successfully in AIDS treatment. The objective of this study was to evaluate the effect of both indinavir and nelfinavir individually, and in association with trimethoprim-sulfamethoxazole (TMP/SMX), on renal function in Wistar rats.Methods: Doses of indinavir (80 mg/kg body weight [BW] daily), nelfinavir (75 mg/kg BW daily) and TMP/SMX (100 mg TMP/kg BW daily) were given by gavage for 15 days. Seven groups were studied: control, vehicle, TMP/SMX, indinavir, indinavir+TMP/SMX, nelfinavir, and nelfinavir+TMP/SMX.Results: No changes were observed in body weight, urine volume and blood pressure. The vehicle group did not differ from the control group. TMP/SMX induced a small decrease in inulin clearance with no tubular alterations. Indinavir decreased inulin clearance (indinavir: 0.48 +/- 0.03 vs control: 0.93 +/- 0.08, P<0.001) and renal blood flow (indinavir: 6.2 +/- 0.2 vs control: 8.0 +/- 0.3, P<0.05). These effects were potentiated by TMP/SMX, which produced high vasoconstriction associated with alterations in tubular functions, characterised by increased fractional excretion of sodium (indinavir+TMP/SMX: 1.14 +/- 0.16 vs control: 0.39 +/- 0.07, P<0.01). Nelfinavir either alone or in combination with TMP/SMX did not change the renal function of the rats.Conclusion: These results suggest that indinavir nephrotoxicity in rats is potentiated by TMP/SMX and that nelfinavir alone or in combination with TMP/SMX is not nephrotoxic.USP, Lab Pesquisa Basica, Fac Med, Disciplina Nefrol, BR-09500900 Sao Paulo, BrazilUniv Fed Sao Paulo, Sao Paulo, BrazilUniv Fed Sao Paulo, Sao Paulo, BrazilWeb of Science181-184engInt Medical Press LtdAntiviral TherapyTrimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicityinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/426102021-10-05 22:00:45.614metadata only accessoai:repositorio.unifesp.br:11600/42610Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652021-10-06T01:00:45Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.en.fl_str_mv Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
title Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
spellingShingle Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
Araujo, Magali de [UNIFESP]
title_short Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
title_full Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
title_fullStr Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
title_full_unstemmed Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
title_sort Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity
author Araujo, Magali de [UNIFESP]
author_facet Araujo, Magali de [UNIFESP]
Seguro, Antonio Carlos
author_role author
author2 Seguro, Antonio Carlos
author2_role author
dc.contributor.institution.none.fl_str_mv Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Araujo, Magali de [UNIFESP]
Seguro, Antonio Carlos
description Objectives: Indinavir is a widely prescribed protease inhibitor in the treatment of HIV infection. It has been associated with nephrolithiasis, crystalluria and tubulointerstitial nephritis. Nelfinavir is another protease inhibitor used successfully in AIDS treatment. The objective of this study was to evaluate the effect of both indinavir and nelfinavir individually, and in association with trimethoprim-sulfamethoxazole (TMP/SMX), on renal function in Wistar rats.Methods: Doses of indinavir (80 mg/kg body weight [BW] daily), nelfinavir (75 mg/kg BW daily) and TMP/SMX (100 mg TMP/kg BW daily) were given by gavage for 15 days. Seven groups were studied: control, vehicle, TMP/SMX, indinavir, indinavir+TMP/SMX, nelfinavir, and nelfinavir+TMP/SMX.Results: No changes were observed in body weight, urine volume and blood pressure. The vehicle group did not differ from the control group. TMP/SMX induced a small decrease in inulin clearance with no tubular alterations. Indinavir decreased inulin clearance (indinavir: 0.48 +/- 0.03 vs control: 0.93 +/- 0.08, P<0.001) and renal blood flow (indinavir: 6.2 +/- 0.2 vs control: 8.0 +/- 0.3, P<0.05). These effects were potentiated by TMP/SMX, which produced high vasoconstriction associated with alterations in tubular functions, characterised by increased fractional excretion of sodium (indinavir+TMP/SMX: 1.14 +/- 0.16 vs control: 0.39 +/- 0.07, P<0.01). Nelfinavir either alone or in combination with TMP/SMX did not change the renal function of the rats.Conclusion: These results suggest that indinavir nephrotoxicity in rats is potentiated by TMP/SMX and that nelfinavir alone or in combination with TMP/SMX is not nephrotoxic.
publishDate 2002
dc.date.issued.fl_str_mv 2002-09-01
dc.date.accessioned.fl_str_mv 2018-06-15T13:50:16Z
dc.date.available.fl_str_mv 2018-06-15T13:50:16Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Antiviral Therapy. London: Int Medical Press Ltd, v. 7, n. 3, p. 181-184, 2002.
dc.identifier.uri.fl_str_mv http://repositorio.unifesp.br/11600/42610
https://www.intmedpress.com/journals/avt/abstract.cfm?id=1223&pid=88
dc.identifier.issn.none.fl_str_mv 1359-6535
dc.identifier.wos.none.fl_str_mv WOS:000179501500005
identifier_str_mv Antiviral Therapy. London: Int Medical Press Ltd, v. 7, n. 3, p. 181-184, 2002.
1359-6535
WOS:000179501500005
url http://repositorio.unifesp.br/11600/42610
https://www.intmedpress.com/journals/avt/abstract.cfm?id=1223&pid=88
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv Antiviral Therapy
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 181-184
dc.publisher.none.fl_str_mv Int Medical Press Ltd
publisher.none.fl_str_mv Int Medical Press Ltd
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv
_version_ 1802764107269537792